Generex Biotechnology Corp. (OTCMKTS:GNBT) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.  Our company creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.

The company goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering.  We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.

For more information please contact our Investor Relations:
Tel: 1-800-391-6755 Ext. 222
or email us at
investor@generex.com

 Generex Biotechnology Corp. is Traded on the OTC Markets our Trading Symbol is OTCMKTS:GNBT click the image above for our current stock price.

 Generex Biotechnology Corp. is SEC Reporting - Current and all our filings can be found on the SEC Edgar Database click on the image above for all our filings.

To read the transcript of the February 22, 2017 Generex Investor Call please click here.

To listen to the recording of the February 22, 2017 Generex Investor Call please click here.
Investor
​Relations
Generex
​Investor Call
Press Releases
  1. Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. to Its Board of Directors
    January 25,2017
    MIRAMAR, Fla. & TORONTO--(BUSINESS WIRE)-- Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that Dr. Yutaka Niihara, M.D., M.P.H., Chairman & Chief Executive Officer of Emmaus Life Sciences, Inc. (www.emmauslifesciences.com), has joined the Generex Board of Directors as its Executive Chairman.
    READ MORE
  2. Generex Announces Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc.
    January 23,2014
    MIRAMAR, Fla. & TORONTO--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 16, 2017 it entered into a letter of intent (the “LOI”) for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc. (www.emmauslifesciences.com) (“Emmaus”). The Company filed a Form 8-K Current Report in respect of the LOI with the U.S. Securities and Exchange Commission (SEC) (www.sec.gov) on Friday, January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms.
    READ MORE
  3. Generex Announces Closing of Acquisition of Controlling Equity Interest in Hema Diagnostic Systems
    January 23,2014
    MIRAMAR, Florida & TORONTO, Canada, January 23, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 19, 2017 it consummated the previously announced acquisition of a controlling equity interest in Hema Diagnostic Systems, LLC (www.hemadiagnosticsystems.com) (“HDS”). The Company filed a Form 8-K Current Report in respect of the acquisition with the U.S. Securities and Exchange Commission (www.sec.gov) on Friday, January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms and the business of HDS. It also includes the audited financial statements of HDS.
    READ MORE
  4. Generex Announces Investor Conference Call
    January 28,2017
    MIRAMAR, Florida, January 30, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it will hold an investor conference call at 10 a.m. Eastern time on Wednesday, February 22, 2017. Dial-in instructions will be issued prior to the date of the call.
    READ MORE
  5. Generex Provides Update on Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc.
    February 9, 2017
    MIRAMAR, Florida & TORONTO, Canada, February 9, 2017 (BUSINESS WIRE) – On January 23, 2017 Generex Biotechnology Corporation (OTCPink:GNBT) announced a letter of intent for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc. (www.emmauslifesciences.com) (“Emmaus”). The Company filed a Form 8-K Current Report in respect of the transaction with the U.S. Securities and Exchange Commission (SEC) (www.sec.gov) on January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms. Generex today announced that Emmaus has granted to Generex an extension of the payment date for an interim cash consideration payment in the amount of $1,500,000 to February 16, 2017.
    READ MORE
  6. Generex Announces Elimination of Outstanding Derivative Securities
    February 15, 2017
    MIRAMAR, Florida & TORONTO, Canada, February 15, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it has achieved the elimination of its outstanding derivative securities.
    READ MORE
  7. Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017
    February 21, 2017
    MIRAMAR, Florida, February 21, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, Wednesday, February 22, 2017, at 10 am. Eastern time:
    READ MORE
  8. Generex Announces Reverse Stock Split
    March 14, 2017
    MIRAMAR, Florida & TORONTO, Canada, March 14, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company’s common stock will begin trading on a split-adjusted basis.
    READ MORE
For all Archived Press Releases please click here